SCHEMBL29310229

SCHEMBL29310229

CN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4cccc(N5CCCC5=O)n4)n3)cc2)CC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.47
▸ WEE1 P30291 5/20 0.44
▸ FLT3 P36888 6/20 0.42
▸ CDK7 P50613 5/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ FYN P06241 2/20 0.42
▸ CSF1R P07333 2/20 0.42
▸ RET P07949 2/20 0.42
▸ FGFR1 P11362 2/20 0.42
▸ CDK5 Q00535 2/20 0.42
▸ PRKAA1 Q13131 2/20 0.42
▸ MAPK8 P45983 2/20 0.42
▸ MAPK9 P45984 2/20 0.42
▸ AURKA O14965 2/20 0.42
▸ ALK Q9UM73 2/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ PAK4 O96013 1/20 0.42
▸ LCK P06239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30997639 1.00 SLC2A1 (0.47) SLC2A1WEE1FLT3CDK7JAK2
SCHEMBL29310117 0.91 SLC2A1 (0.57) SLC2A1WEE1FLT3CDK7JAK2
SCHEMBL30997622 0.91 SLC2A1 (0.57) SLC2A1WEE1FLT3CDK7JAK2
SCHEMBL29310230 0.84 WEE1 (0.48) SLC2A1WEE1BTKTNK2EGFR
SCHEMBL29310236 0.84 BTK (0.49) SLC2A1WEE1BTKTNK2EGFR
SCHEMBL30997606 0.83 MAP4K1 (0.39) SLC2A1WEE1MAPK8MAPK9AURKA
SCHEMBL29310220 0.83 MAP4K1 (0.39) SLC2A1WEE1MAPK8MAPK9AURKA
SCHEMBL30997653 0.82 SLC2A1 (0.44) SLC2A1WEE1FLT3CDK7JAK2
SCHEMBL30997625 0.82 SLC2A1 (0.44) SLC2A1WEE1FLT3CDK7JAK2
SCHEMBL29310214 0.82 SLC2A1 (0.44) SLC2A1WEE1FLT3CDK7JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B SLC2A1 4591/4885WEE1 1/4885FLT3 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback